Ascentage Pharma Group International - Laporan Laba Rugi (TTM)

Ascentage Pharma Group International
US ˙ OTCPK ˙ KYG0519B1023

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Ascentage Pharma Group International menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 14 12 18 23 25 28 69 111 160 210 233 257 239 222 563 903 942 981 686 391
Change (%) -8.65 41.57 29.37 11.20 10.07 148.33 59.73 44.71 30.90 11.19 10.06 -6.75 -7.24 153.40 60.54 4.30 4.12 -30.08 -43.03
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 2 2 3 5 4 3 5 6 14 22 29 35 33 31 29 27 28 29 32 36
Change (%) -3.20 65.84 39.70 -13.47 -15.57 36.54 26.76 140.95 58.50 29.85 22.99 -6.53 -6.99 -5.07 -5.34 2.98 2.90 11.33 10.18
% of Revenue 14.90 15.79 18.50 19.98 15.54 11.92 6.56 5.20 8.66 10.49 12.25 13.69 13.72 13.76 5.15 3.04 3.00 2.97 4.72 9.13
Gross Operating Profit 12 10 14 18 21 25 65 105 146 188 205 222 206 191 534 876 914 952 653 355
Change (%) -9.61 37.02 27.02 17.36 14.79 163.47 62.04 39.43 28.28 9.00 8.26 -6.79 -7.28 178.68 64.12 4.34 4.16 -31.35 -45.67
% of Revenue 85.10 84.21 81.50 80.02 84.46 88.08 93.44 94.80 91.34 89.51 87.75 86.31 86.28 86.24 94.85 96.96 97.00 97.03 95.28 90.87
SG&A 146 130 137 143 167 191 231 270 299 328 339 349 363 376 377 378 381 383 414 444
Change (%) -10.69 4.92 4.69 16.80 14.38 20.70 17.15 10.65 9.62 3.20 3.10 3.94 3.79 0.26 0.26 0.62 0.62 7.94 7.36
% of Revenue 1,070.82 1,046.92 775.86 627.85 659.46 685.28 333.06 244.27 186.77 156.41 145.17 135.98 151.57 169.59 67.10 41.91 40.43 39.07 60.32 113.66
R&D 540 565 598 631 699 766 778 790 767 743 727 712 709 707 774 841 894 947 989 1,032
Change (%) 4.46 5.85 5.53 10.77 9.72 1.56 1.53 -2.99 -3.08 -2.13 -2.17 -0.32 -0.32 9.50 8.67 6.30 5.93 4.46 4.27
% of Revenue 3,965.39 4,534.71 3,390.53 2,765.81 2,755.07 2,746.30 1,123.12 713.91 478.58 354.35 311.91 277.23 296.36 318.48 137.62 93.16 94.95 96.59 144.32 264.14
OpEx 688 697 738 778 870 961 1,014 1,067 1,080 1,093 1,094 1,096 1,105 1,114 1,181 1,247 1,303 1,359 1,435 1,511
Change (%) 1.23 5.85 5.52 11.74 10.50 5.49 5.20 1.25 1.23 0.11 0.11 0.84 0.83 5.98 5.64 4.50 4.31 5.59 5.29
% of Revenue 5,051.11 5,597.42 4,184.89 3,413.63 3,430.07 3,443.50 1,462.74 963.38 674.01 521.25 469.33 426.90 461.65 501.83 209.87 138.10 138.38 138.63 209.36 386.93
Operating Income -675 -684 -720 -756 -844 -933 -945 -956 -920 -883 -861 -839 -865 -892 -618 -344 -361 -379 -750 -1,121
Change (%) 1.43 5.20 4.94 11.75 10.52 1.21 1.20 -3.79 -3.94 -2.51 -2.58 3.16 3.06 -30.71 -44.33 5.04 4.80 97.94 49.48
% of Revenue -4,951.11 -5,497.42 -4,084.89 -3,313.63 -3,330.07 -3,343.50 -1,362.74 -863.38 -574.01 -421.25 -369.33 -326.90 -361.65 -401.83 -109.87 -38.10 -38.38 -38.63 -109.36 -286.93
Interest Expense -5 -6 -10 -13 -15 -17 -22 -27 -40 -53 -70 -86 -91 -96 -87 -77 -71 -64 -61 -58
Change (%) 20.94 52.35 34.36 15.34 13.30 31.96 24.22 46.23 31.62 31.87 24.17 5.57 5.27 -9.70 -10.75 -8.37 -9.13 -4.87 -5.12
% of Revenue -37.95 -50.24 -54.07 -56.15 -58.24 -59.95 -31.86 -24.77 -25.03 -25.17 -29.85 -33.68 -38.13 -43.27 -15.42 -8.57 -7.53 -6.57 -8.94 -14.89
Net Income -922 -678 -706 -735 -759 -782 -797 -812 -848 -883 -881 -879 -902 -926 -643 -360 -383 -405 -782 -1,159
Change (%) -26.51 4.24 4.07 3.22 3.12 1.92 1.88 4.34 4.16 -0.25 -0.25 2.68 2.61 -30.54 -43.96 6.27 5.90 92.96 48.18
% of Revenue -6,765.41 -5,442.62 -4,007.48 -3,223.89 -2,992.46 -2,803.38 -1,150.57 -733.89 -529.12 -421.02 -377.70 -342.31 -376.94 -416.98 -114.30 -39.90 -40.65 -41.34 -114.10 -296.77

Source: Capital IQ

Other Listings
HK:6855 HK$ 79.35
DE:36X € 8.65
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista